-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Urothelial carcinoma (UC) with FGFR3 gene alteration is associated with a non-T cell inflammatory phenotype and therefore is considered to be less responsive to immune checkpoint block (ICB)
Urothelial carcinoma (UC) with FGFR3 gene alteration is associated with a non-T cell inflammatory phenotype and therefore is considered to be less responsive to immune checkpoint block (ICB)
109 patients received single-drug PD1 or PD-L1 inhibitor treatment, 108 patients could be evaluated for efficacy, and 103 patients could be subjected to somatic cell sequencing of FGFR3 gene changes
109 patients received single-drug PD1 or PD-L1 inhibitor treatment, 108 patients could be evaluated for efficacy, and 103 patients could be subjected to somatic cell sequencing of FGFR3 gene changes
The median OS of FGFR3 genetically altered patients and FGFR3 wild-type patients were 9.
Prognosis
There was no significant difference in the median duration of response between FGFR3 genetically altered patients and FGFR3 wild-type patients, which were 15.
There was no significant difference in the median duration of response between FGFR3 genetically altered patients and FGFR3 wild-type patients, which were 15.
Efficacy evaluation
The FGFR3 RNA level of FGFR3 gene alteration patients is higher than that of wild-type patients, and the FGFR3 gene mutation and fusion FGFR3 RNA level are similar
The FGFR3 RNA level of FGFR3 gene alteration patients is higher than that of wild-type patients, and the FGFR3 gene mutation and fusion FGFR3 RNA level are similar
Signal pathway changes
And according to criteria different subtypes, FGFR3 gene changes mainly in the luminal and luminal- papillary subtype, and is also found to FGFR3 RNA with high expression levels
And according to criteria different subtypes, FGFR3 gene changes mainly in the luminal and luminal- papillary subtype, and is also found to FGFR3 RNA with high expression levels
Comparison of different subtypes
In summary, metastatic urothelial carcinoma (UC) with FGFR3 gene alteration has no effect on the immune checkpoint block (ICB) response, and does not affect the patient's prognosis
In summary, metastatic urothelial carcinoma (UC) with FGFR3 gene alteration has no effect on the immune checkpoint block (ICB) response, and does not affect the patient's prognosis
.
Metastatic urothelial carcinoma (UC) with FGFR3 gene alteration has no effect on the immune checkpoint block (ICB) response, and does not affect the patient's prognosis
.
Metastatic urothelial carcinoma (UC) with FGFR3 gene alteration has no effect on the immune checkpoint block (ICB) response, and does not affect the patient's prognosis
.
Original source:
Original source:Rose TL, Weir WH, Mayhew GM, et al.
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
Br J Cancer.
2021 Jul 22.
doi: 10.
1038/s41416-021- 01488-6.
Epub ahead of print.
PMID: 34294892.
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
Br J Cancer.
2021 Jul 22.
doi: 10.
1038/s41416-021- 01488-6.
Epub ahead of print.
PMID: 34294892.
Leave a message here